242 related articles for article (PubMed ID: 11532635)
21. [Comparison of conditioning regimens containing or no fludarabine in nonmyeloablative allogeneic peripheral blood stem cell transplantation].
Guo M; Yu CL; Wang DH; Qiao JH; Sun WJ; Shi BF; Zhang S; Sun QY; Yao B; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):413-5. PubMed ID: 14642178
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
23. Clinical Relevance of Apheretic Graft Composition in Patients With Acute Myeloblastic Leukemia Who Received a Busulfan-Fludarabine-Antithymocyte Globulin Conditioning Regimen for Allogeneic Transplant.
Yeral M; Kasar M; Boga C; Kozanoglu I; Ozdogu H; Sariturk C
Exp Clin Transplant; 2015 Oct; 13(5):453-60. PubMed ID: 26103468
[TBL] [Abstract][Full Text] [Related]
24. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
25. A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation.
Shapira MY; Or R; Resnick IB; Bitan M; Ackerstein A; Samuel S; Elad S; Zilberman I; Miron S; Slavin S
Bone Marrow Transplant; 2003 Sep; 32(6):557-61. PubMed ID: 12953126
[TBL] [Abstract][Full Text] [Related]
26. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
27. [Allogeneic blood stem cell transplantation in high-risk patients after conditioning with treosulfan and fludarabine].
Casper J; Wilhelm S; Steiner B; Wolff D; Grobe N; Hähling D; Hartung G; Hilgendorf I; Lück A; Junghanss C; Kahl C; Baumgart J; Pichlmeier U; Freund M
Dtsch Med Wochenschr; 2005 Sep; 130(38):2125-9. PubMed ID: 16172951
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
Chunduri S; Dobogai LC; Peace D; Saunthararajah Y; Quigley J; Chen YH; Mahmud N; Hurter E; Beri R; Rondelli D
Bone Marrow Transplant; 2008 Jun; 41(11):935-40. PubMed ID: 18264144
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of the fludarabine busulfan 3 days and ATG 2 days reduced toxicity conditioning in 51 allogeneic hematopoietic stem cell transplantation: a single-center experience.
Chantepie SP; Gac AC; Reman O
Leuk Res; 2014 May; 38(5):569-74. PubMed ID: 24655805
[TBL] [Abstract][Full Text] [Related]
30. Myeloablative BU, fludarabine, antithymocyte globulin and low-dose TBI in the treatment of juvenile myelomonocytic leukaemia with allogeneic haematopoietic cell transplantation.
Guilcher GM; Moorjani R; Truong TH; Lewis VA
Bone Marrow Transplant; 2015 Mar; 50(3):455-6. PubMed ID: 25486583
[No Abstract] [Full Text] [Related]
31. Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.
Lee JH; Lee JH; Kang YK; Lee JS; Kim WK; Lee KH
Haematologica; 2001 Oct; 86(10):1114-5. PubMed ID: 11602425
[No Abstract] [Full Text] [Related]
32. Early full donor myeloid chimerism after reduced-intensity stem cell transplantation using a combination of fludarabine and busulfan.
Niiya H; Kanda Y; Saito T; Ohnishi T; Kanai S; Kawano Y; Kamijo K; Iizuka A; Yakushijin K; Ueda K; Chizuka A; Iijima K; Ohnishi M; Nakai K; Makimoto A; Tanosaki R; Tobinai K; Wakasugi H; Takaue Y; Mineishi S
Haematologica; 2001 Oct; 86(10):1071-4. PubMed ID: 11602413
[TBL] [Abstract][Full Text] [Related]
33. The gut mucosa barrier is preserved during allogeneic, haemopoietic stem cell transplantation with reduced intensity conditioning.
Johansson JE; Brune M; Ekman T
Bone Marrow Transplant; 2001 Oct; 28(8):737-42. PubMed ID: 11781624
[TBL] [Abstract][Full Text] [Related]
34. Adult recipients of matched related donor blood cell transplants given myeloablative regimens including pretransplant antithymocyte globulin have lower mortality related to graft-versus-host disease: a matched pair analysis.
Russell JA; Turner AR; Larratt L; Chaudhry A; Morris D; Brown C; Quinlan D; Stewart D
Biol Blood Marrow Transplant; 2007 Mar; 13(3):299-306. PubMed ID: 17317583
[TBL] [Abstract][Full Text] [Related]
35. Non-TBI stem cell transplantation protocol for Fanconi anaemia using HLA-compatible sibling and unrelated donors.
de la Fuente J; Reiss S; McCloy M; Vulliamy T; Roberts IA; Rahemtulla A; Dokal I
Bone Marrow Transplant; 2003 Oct; 32(7):653-6. PubMed ID: 13130311
[TBL] [Abstract][Full Text] [Related]
36. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
[TBL] [Abstract][Full Text] [Related]
37. [Seventeen cases of nonmyeloablative stem cell transplantation using a conditioning regimen containing fludarabine].
Wu DP; Ma X; Sun AN; Fu ZZ; Tang XW; Qiu HY; Miao M; Liu YJ; Li CX; Xia XM; Lin BJ
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):410-2. PubMed ID: 14642177
[TBL] [Abstract][Full Text] [Related]
38. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Alessandrino EP; Bernasconi P; Colombo AA; Caldera D; Malcovati L; Troletti D; Vanelli L; Varettoni M; Montanari F; Lazzarino M
Bone Marrow Transplant; 2004 Dec; 34(12):1039-45. PubMed ID: 15516936
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic cell transplantation from an HLA-mismatched familial donor is feasible without ex vivo-T cell depletion after reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin.
Lee KH; Lee JH; Lee JH; Kim DY; Kim SH; Shin HJ; Lee YS; Kang YA; Seol M; Ryu SG
Biol Blood Marrow Transplant; 2009 Jan; 15(1):61-72. PubMed ID: 19135944
[TBL] [Abstract][Full Text] [Related]
40. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study.
Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH
Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
